These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37787009)

  • 1. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
    Anastasiou OE; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Heidrich B; Mederacke I; von der Leyen H; Kahlhöfer J; von Karpowitz M; Hardtke S; Cornberg M; Yurdaydin C; Wedemeyer H
    Liver Int; 2024 Jan; 44(1):139-147. PubMed ID: 37787009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
    Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
    Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
    Dinkelborg K; Kahlhöfer J; Dörge P; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP; Wedemeyer H; Deterding K;
    Liver Int; 2023 Aug; 43(8):1663-1676. PubMed ID: 37183524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: antiviral treatment for hepatitis D.
    Triantos C; Kalafateli M; Nikolopoulou V; Burroughs A
    Aliment Pharmacol Ther; 2012 Mar; 35(6):663-73. PubMed ID: 22273482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
    Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
    N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
    Bremer B; Anastasiou OE; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Radu M; Idilman R; Manns MP; Cornberg M; Yurdaydin C; Wedemeyer H
    Liver Int; 2021 Feb; 41(2):295-299. PubMed ID: 33217778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
    Anastasiou OE; Yurdaydin C; Maasoumy B; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Radu M; Liebig S; Bantel H; Bremer B; Manns MP; Cornberg M; Wedemeyer H
    J Viral Hepat; 2021 Feb; 28(2):410-419. PubMed ID: 33185325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
    Ahn SH; Marcellin P; Ma X; Caruntu FA; Tak WY; Elkhashab M; Chuang WL; Tabak F; Mehta R; Petersen J; Guyer W; Jump B; Chan A; Subramanian M; Crans G; Fung S; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HLY
    Dig Dis Sci; 2018 Dec; 63(12):3487-3497. PubMed ID: 30136045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
    Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
    Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
    Hu X; Luo H; Tan G; Li Y; Qin B
    BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
    Wranke A; Hardtke S; Heidrich B; Dalekos G; Yalçin K; Tabak F; Gürel S; Çakaloğlu Y; Akarca US; Lammert F; Häussinger D; Müller T; Wöbse M; Manns MP; Idilman R; Cornberg M; Wedemeyer H; Yurdaydin C
    J Viral Hepat; 2020 Dec; 27(12):1359-1368. PubMed ID: 32707605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
    Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C treatment in näive patients.
    Daruich J
    Ann Hepatol; 2010; 9 Suppl():65-71. PubMed ID: 20713999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.